You are here

Trevor Crowell, M.D., Ph.D

Associate Director of the Department of Epidemiology and Threat Assessment

Dr. Crowell is Associate Director of the Department of Epidemiology and Threat Assessment at MHRP, where he oversees cohorts and other epidemiologic studies of HIV, sexually transmitted infections, and other infectious disease threats to global public health and U.S. military force readiness.

Dr. Crowell is a physician specialist in infectious diseases who received his M.D. from the University of Southern California Keck School of Medicine and his Ph.D. in clinical investigation from the Johns Hopkins Bloomberg School of Public Health. He completed his residency in internal medicine and international health at University Hospitals Case Medical Center and his fellowship in infectious diseases at the Johns Hopkins University School of Medicine.

Dr. Crowell is an assistant professor in the Division of Infectious Diseases at the Uniformed Services University and has an adjunct appointment at Johns Hopkins University, where he provides inpatient consultative clinical care. He is a Deputy Editor for the Journal of the International AIDS Society and serves on the editorial boards of AIDS and AIDS Research and Therapy. He is an active investigator with the NIH-sponsored AIDS Clinical Trials Group (ACTG), having served as an elected member of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group and on the leadership teams for multinational studies of acute HIV infection and the use of broadly-neutralizing antibodies for HIV therapy. He is a past recipient of the ACTG John Carey Young Investigator Award.

Dr. Crowell has published extensively on clinical outcomes among persons living with or at risk for HIV, with a focus on U.S. military service members, sexual and gender minority populations, elite controllers, and individuals diagnosed during acute HIV infection. His current research also includes clinical trials of novel interventions to achieve HIV remission as well as preventive vaccine candidates for HIV and other infectious diseases.

 

Select Publications

  1. Crowell TA, Danboise B, Parikh AP, Esber AL, Dear N, Coakley P, Kasembeli A, Maswai J, Khamadi SA, Bahemana E, Iroezindu M, Kiweewa F, Owuoth J, Freeman J, Jagodzinski LL, Malia JA, Eller LA, Tovanabutra S, Peel SA, Ake JA, Polyak CS for the AFRICOS Study Group. “Pre-Treatment and Acquired Antiretroviral Drug Resistance among Persons Living with HIV in Four African Countries.” Clinical Infectious Diseases. 2020 Aug 12:ciaa1161 [Online ahead of print]
  2. Crowell TA, Pinyakorn S, Sacdalan C, Kroon E, Colby DJ, Puttamaswin S, Ubolyam S, Trichavaroj R, Butterworth O, Turk E, McCullough C, Chomont N, de Souza M, Robb ML, Phanuphak N, Ananworanich J for the RV254/SEARCH010 Study Group. “Viral Blips after Treatment Initiation during Acute HIV Infection.” Clinical Infectious Diseases. 2020 Jun 10;70(12):2706-2709.
  3. Esber A, Coakley P, Ake JA, Bahemana E, Adamu Y, Kiweewa F, Maswai J, Owuoth J, Robb ML, Polyak CS, Crowell TA for the AFRICOS Study Group. “Decreasing Time to Antiretroviral Therapy Initiation after HIV Diagnosis in a Clinic-Based Observational Cohort Study in Four African Countries.” Journal of the International AIDS Society. 2020 Feb;23(2):e25446.
  4. Esber A, Polyak C, Kiweewa F, Maswai J, Owuoth J, Maganga L, Adamu Y, Hickey P, Ake J, Crowell TA. “Persistent Low-Level Viremia Predicts Subsequent Virologic Failure. Is It Time to Change the Third 90?” Clinical Infectious Diseases. 2019 Sep 1;69(5):805-812.
  5. Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Poulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O’Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J for the RV397 Study Group. “Safety and Efficacy of VRC01 Broadly Neutralising Antibodies in Adults with Acutely Treated HIV (RV 397): a Phase 2, Randomised, Double-blind, Placebo-controlled Trial.” The Lancet HIV. 2019 May;6(5):e297-e306.
  6. Crowell TA, Baral SD, Schwartz S, Nowak RG, Kokogho A, Adebajo S, Keshinro B, Makanjuola O, Michael NL, Robb ML, Charurat ME, Ake JA for the TRUST/RV368 Study Group. “Time to Change the Paradigm: Limited Condom and Lubricant Use among Nigerian Men who have Sex with Men and Transgender Women despite Availability and Counseling.” Annals of Epidemiology. 2019 Mar;31:11-19.e3.
  7. Crowell TA, Colby DJ, Pinyakorn S, Fletcher JLK, Kroon E, Schuetz A, Krebs SJ, Slike BM, Leyre L, Chomont N, Jagodzinski LL, Sereti I, Utay NS, Dewar R, Rerknimitr R, Chomchey N, Trichavaroj R, Valcour VG, Spudich S, Michael NL, Robb ML, Phanuphak N, Ananworanich J for the RV254/SEARCH010 Study Group. “Acute Retroviral Syndrome is Associated with High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments.” Clinical Infectious Diseases. 2018 May 2;66(10):1540-1549.
  8. Crowell TA, Keshinro B, Baral SD, Schwartz SR, Nowak RG, Adebajo S, Blattner WA, Charurat ME, Ake J for the TRUST/RV368 Study Group. “Stigma, Access to Healthcare, and HIV Risks among Men who Sell Sex to Men in Nigeria.” Journal of the International AIDS Society. 2017 Apr 20;20(1):21489.
  9. Crowell TA, Phanuphak N, Pinyakorn S, Kroon E, Fletcher JLK, Colby D, Tipsuk S, Karnsomlap P, Laopraynak N, O’Connell RJ, Robb ML, Ananworanich J for the RV254/SEARCH010 Study Group. “Virologic Failure is Uncommon after Treatment Initiation during Acute HIV Infection.” AIDS. 2016 Jul 31;30(12):1943-50.
  10. Crowell TA, Ganesan A, Berry SA, Deiss RG, Agan BK, Okulicz JF for the Infectious Disease Clinical Research Program (IDCRP) HIV Working Group. “Hospitalizations among HIV Controllers and Persons with Medically-Controlled HIV in the U.S. Military HIV Natural History Study.” Journal of the International AIDS Society. 2016 Mar 7;19(1):20524.